Gerald McMahon

Biochemistry, Genetics and Molecular Biology · Life Sciences

47h-index16.2kcitations113works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Angiogenesis and VEGF in Cancer(31), Cancer, Hypoxia, and Metabolism(26), Liver physiology and pathology(15), Mast cells and histamine(13), PI3K/AKT/mTOR signaling in cancer(12)

Publications113 total

587 Phase 1b/2 dose escalation and expansion study of STC-15, a METTL3 inhibitor, in combination with toripalimab, an anti-PD-1 antibody, in patients with advanced solid tumors
Regular and Young Investigator Award Abstracts·2025Open Access
Supplementary Table S1 from Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors
2023Open Access
Supplementary Figure and Table Legends from Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors
2023Open Access
Data from Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors
2023Open Access
Data from KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells
2023Open Access
London et al_Supplementary Methods from KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells
2023Open Access
Tables S1 and S2 from KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells
2023Open Access
Data from Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors
2023Open Access
Supplementary Table S1 from Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors
2023Open Access
Figure S1 from KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells
2023Open Access
Tables S1 and S2 from KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells
2023Open Access
Figure S1 from KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells
2023Open Access
Supplementary Figures S1-S4 from Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors
2023Open Access
Supplementary Methods and References from Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors
2023Open Access
Supplementary Figures S1-S4 from Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors
2023Open Access
London et al_Supplementary Methods from KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells
2023Open Access
Supplementary Figure and Table Legends from Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors
2023Open Access
Supplementary Methods and References from Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors
2023Open Access
Data from KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells
2023Open Access
ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC
PLoS ONE·2017· 29 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Cho Tang(12), Kenneth E. Lipson(9), Li Sun(8), Congxin Liang(7), Julie M. Cherrington(6), Randall Schreck(5), Laura K. Shawver(5), Dirk B. Mendel(4), Peter Hirth(4), Flora Tang(4), Harald App(4), Aviv Gazit(4), Audie Rice(4), Gerald N. Wogan(4), Robert A. Blake(3), Stevan R. Hubbard(3), T. Annie T. Fong(3), K. Peter Hirth(3), Narmada Shenoy(3), Ngoc Quang Tran(3)